Pulmonary edema refers to fluid accumulation in the air sacs of the lungs, known as alveoli. It causes difficulty in breathing, shortness of breath, coughing, and wheezing. Pulmonary edema is often caused by heart failure, fluid overload, lung disease such as pneumonia, or acute respiratory distress syndrome. The therapies for pulmonary edema include medications to remove excess fluid from the lungs or improve heart and lung function. Drugs such as diuretics, vasodilators, inotropes, corticosteroids, and bronchodilators are commonly used to treat pulmonary edema.

The global Pulmonary Edema Therapeutics Market is estimated to be valued at US$ 13990.01 Bn in 2023 and is expected to exhibit a CAGR of 9.8% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.

Market key trends:

The growing prevalence of pulmonary edema worldwide due to rising cases of heart failure, lung infections, and other underlying conditions is a major factor driving the pulmonary edema therapeutics market. For instance, according to the American Heart Association statistics, over 6 million Americans suffer from heart failure and approximately half of those people developing acute pulmonary edema each year will die from it or related complications. Moreover, technological advancements in drugs and devices for management of pulmonary edema symptoms coupled with increasing availability of advanced treatment options are further contributing to the market growth over the forecast period. However, high costs associated with therapy and devices for pulmonary edema poses a major challenge to market players.

SWOT Analysis
Strength: The market has a large patient pool suffering from pulmonary edema due to rising cases of heart failure and lung disorders. This ensures continuous demand for therapies.
Weakness: Long development timelines and high costs associated with drug development restrict market growth.
Opportunity: Developing regions like Asia Pacific offer high growth potential owing to improving healthcare infrastructure and increasing investment in R&D.
Threats: Stringent regulatory framework for drug approval delays market launch of new therapies. Stiff competition from generic drug manufacturers further limits scope for high prices.

Key Takeaways

The Global Pulmonary Edema Therapeutics Market Demand is expected to witness high growth. The global Pulmonary Edema Therapeutics Market is estimated to be valued at US$ 13990.01 Bn in 2023 and is expected to exhibit a CAGR of 9.8% over the forecast period 2024 to 2031.

North America dominates the market currently due to advanced healthcare facilities and higher adoption of new therapies. However, Asia Pacific is likely to emerge as the fastest growing regional market in the coming years.

Key players operating in the Pulmonary Edema Therapeutics are Knoll Inc., Freudenberg Group, Avgol Ltd., Carnegie Fabrics LLC, Eximius Incorporation, Berry Global Group Inc., Asahi Kasei Corporation, Ahlstrom Munksjo OYJ, Kimberly-Clark Corporation, and Paramount Tech Fab Industries, among others. Growth strategies adopted by major players include new product launches and geographic expansions to strengthen market presence.

For more details on the report, Read- https://www.pressreleasebulletin.com/pulmonary-edema-therapeutics-market-demand-share-analysis/

Get more insights on this topic: https://whotimes.com/beyond-dna-exploring-the-frontier-of-creation-through-the-lens-of-synthetic-biology/